Title: Modafinil: the unique properties of a new stimulant.
Abstract: Modafinil, a novel stimulant which has several remarkable features that distinguish it from other stimulants, has been developed by Lafon, a French pharmaceutical company. Unlike the amphetamines, for example, modafinil is reported to have minimal peripheral side effects at therapeutic doses. It also appears to have a low abuse potential, does not interfere with normal sleep, and does not seem to produce tolerance. It improves vigilance especially in sleep-deprived subjects. It has been used clinically for up to 3 years in the treatment of narcolepsy and idiopathic hypersomnia. It could be an ideal replacement for amphetamine in short-term operations in which fatigue might threaten the successful completion of a mission. We recommend that military laboratories experienced in studying sustained performance include modafinil or perhaps a more selective alpha 1 receptor agonist in their investigations.
Publication Year: 1991
Publication Date: 1991-05-01
Language: en
Type: article
Indexed In: ['pubmed']
Access and Citation
Cited By Count: 65
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot